Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod

BACKGROUND: Natalizumab significantly reduces the disease activity in patients with relapsing-remitting multiple sclerosis but due to the risk of progressive multifocal leukoencephalopathy it is often discontinued. Fingolimod is seen as an alternative, but there are no long-term analyses of the effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Diem, Lara, Nedeltchev, Krassen, Kahles, Timo, Achtnichts, Lutz, Findling, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6088480/
https://www.ncbi.nlm.nih.gov/pubmed/30116299
http://dx.doi.org/10.1177/1756286418791103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6088480/
https://www.ncbi.nlm.nih.gov/pubmed/30116299
http://dx.doi.org/10.1177/1756286418791103

Ejemplares similares